Timothy F. O’Neill, MD

Internal Medicine, Cardiology

• Certified in Cardiovascular Disease
  American Board of Internal Medicine
  1993 (Recertification 2009)
• Certified in Internal Medicine
  American Board of Internal Medicine
  1990
• National Board Parts I,II,III
  National Board of Medical Examiners
  1985 – 1988

• Los Alamitos Medical Center
  3751 Katella Avenue
  Los Alamitos, California 90720
• MemorialCare Health System
  Long Beach Memorial Medical Center
  2801 Atlantic Avenue
  Long Beach, California 90801
• Lakewood Regional Medical Center
  3700 South Street
  Lakewood, California 90712

• Los Alamitos Cardiovascular/Los Alamitos Internal Group, Inc.
  Cardiologist
  Los Alamitos, California
  February 1997 – Present
• Heart Institute of the Desert
  Rancho Mirage, California
  October 1993 – February 1997

• Pacemaker Fellowship
  Long Beach Memorial Medical Center
  Long Beach, California
  July 1992 – June 1993
• Cardiology Fellowship
  University of California, Irvine Medical Center
  Irvine, California
  July 1990 – June 1993
• Internal Medicine Residency
  University of California, Irvine Medical Center
  Irvine, California
  June 1987 – June 1990
• University of New Mexico School of Medicine
  Doctor of Medicine Degree
  Albuquerque, New Mexico
  August 1983 – May 1987
• Undergraduate Education
  Creighton University
  Omaha, Nebraska
  Bachelor of Arts Degree in History, Summa Cum Laude
  August 1979 – May 1983

• Outstanding Intern Commendation
  Veteran’s Administration Medical Center
  Long Beach, California
  1987
• Four Superior Scholastic Achievement Awards
  Creighton University
  1980 – 1983
• Graduated Summa Cum Laude
  Creighton University
  1983

• Non Invasive Cardiology; Echocardiography: TEE, Dobutamine, Stress Echo
• Invasive Cardiology: Catherization, Permanent Pacemaker Implantation

• AEGIS: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome.
  Sub-Investigator | 2019
  Sponsor: CSL Behring LLC
  NCT03473223
• COVET : Comparison of Oral anticoagulants for extended Venous Thromboembolism (COVET). It is a randomized, open label, active comparator to determine whether the direct oral anticoagulant apixaban and rivaroxaban are safer than warfarin (fewer bleeding complications) and still as effective as warfarin (no increase in recurrent blood clots).
  Sub-Investigator | 2018 – Present
  Sponsor : Patient-Centered Outcomes Research Institute (PCORI)
  NCT03196349
• NODE 301: Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia.
  Sub-Investigator | 2019
  Sponsor: Milestone Pharmaceuticals Inc.
  NCT03464019
• NODE 302: Multi-Centre, Open-Label, Safety Study of Etripamil Nasal Spray in Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (Extension of NODE-301).
  Sub-Investigator | 2019
  Sponsor: Milestone Pharmaceuticals Inc.
  NCT03635996
• PARADISE MI: A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk patients following an acute myocardial infarction.
  Sub-Investigator | 2018 – Present
  Sponsor: Novartis
  NCT02924727
• PEA-VALVE: Phono- and Electrocardiogram Assisted Detection of Valvular Disease. This is data collection of recorded heart sounds + ECGs using Eko Duo and Eko Core devices to further refine and validate algorithms using de-identified diagnosis confirmed by gold-standard echocardiograms.
  Sub-Investigator | 2018 – Present
  Sponsor: Eko Devices
• GALACTIC-HF: Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction.
  Sub-Investigator | 2017 – Present
  Sponsor: Amgen
  NCT02929329
• PROVE-HF: A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
  Sub-Investigator | 2017 – 2019
  Sponsor: Novartis
  NCT02887183
• Barostim Therapy for Heart Failure (BeAT-HF): The Barostim Neo – Baroreflex Activation Therapy for Heart Failure is a prospective, randomized trial in subjects with reduced ejection fraction heart failure.
  Sub-Investigator | 2016 – Present
  Sponsor: CVRx, Inc.
  NCT02627196
• MLHFQ Study: Evaluate and establish content validity of the Minnesota Living with Heart Failure Questionnaire (MLHFQ) in patients with Symptomatic Hypertrophic Cardiomyopathy.
  Sub-Investigator | 2016 – 2017
  Sponsor: Gilead/ICON
• THEMIS- A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus (THEMIS): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS – Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study).
  Sub-Investigator | 2015 – Present
  Sponsor: AstraZeneca
  NCT01991795
• Retrospective Medical Records Review of Participants Interviewed for Study M-12347 (Concept Elicitation Focus Groups and Cognitive Interviews to Develop a New Patient Reported Outcome Instrument in Chronic Heart Failure).
  Sub-Investigator | 2015 – 2016
  Sponsor: Amgen, Evider
• DECLARE-TIMI 58 Dapagliflozin Effect on CardiovascuLAR Events: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.
  Sub-Investigator | 2013 – Present
  Sponsor: AstraZeneca
  NCT01730534
• ODYSSEY EFC11570: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
  Sub-Investigator | 2013 – 2017
  Sponsor: Sanofi
  NCT01663402
• SILVER-AMI Risk Stratification in Older Persons with Acute Myocardial Infarction.
  Sub-Investigator | 2013 – 2017
  Sponsor: Yale University School of Medicine/NIH
  NCT01755052
• RivaroxAFL3003: An Open Label Study Exploring two treatment strategies in patients with Atrial Fibrillation who undergo Percutaneous Coronary Intervention.
  Sub-Investigator | 2013 – 2014
  Sponsor:  Janssen Scientific Affairs/Johnson & Johnson
• Phase III Trial to confirm the Anti-Anginal effect of T-89 in patients with Stable Angina.
  Sub-Investigator | 2013
  Sponsor: Tasly Pharmaceuticals
  NCT0169580
• Cardiovascular Inflammation Reduction Trial (CIRT): Event Driven Trial of weekly Low-Dose Methotrexate in prevention of recurrent cardiovascular events among stable post myocardial infarction patients with Type II Diabetes or Metabolic Syndrome.
  Sub-Investigator | 2013 – 2018
  Sponsor: Center for Cardiovascular Disease Prevention Brigham and Women’s Hospital/National Heart Lung and Blood Institute
  NCT01594333
• User Comprehension Evaluation of a New Cleaning and Disinfection Procedure for the INRatio® 2 PT/INR Monitoring System (ADAPT) BSTE-0159.
  Sub-Investigator | 2012
  Sponsor: Alere San Diego
• Mission® PT Coagulation Monitoring System Clinical Study.
  Sub-Investigator | 2012
  Sponsor: ACON Laboratories, INC.
• The “BRIDGE” Trial (1U01HL08675501A1): Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery.
  Sub-Investigator | 2012 – 2015
  Sponsor: National Institutes of Health (NIH) – National Heart, Lung and Blood Institute (NHLBI)
  NCT00786474
• GLORIA-AF 1160.129: Global Registry on Long-Term Oral Anti-thrombotic Treatment in Patients with Atrial Fibrillation Phase II-III.
  Sub-Investigator | 2012 – Present
  Sponsor: Boehringer Ingelheim
  NCT01468701
• BRADYCARE: Advanced Bradycardia Device Feature Utilization and Clinical Outcomes.
  Sub-Investigator | 2010 – 2012
  Sponsor: St. Jude Medical Center
  NCT01062126
• The PROMISE Trial: PROspective Multicenter Imaging Study for Evaluation of Chest Pain.
  Sub-Investigator | 2010 – 2014
  Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
  NCT01174550
• ORBIT-AF I and II: Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.
  Sub-Investigator | 2010 – 2017
  Sponsor: Janssen Scientific Affairs, LLC
  Collaborator: Duke Clinical Research
  NCT01165710 & NCT01701817
• RATE: Registry of Atrial Tachyarrhythmia/Atrial Fibrillation(AT/AF) Episodes in the Cardiac Rhythm Management (CRM) Device Population.
  Sub-Investigator | 2008 – 2010
  Sponsor: St. Jude Medical Center
  NCT00837798
• FREEDOM: A Frequent Optimization Study the Quick Opt ™ Method.
  Sub-Investigator | 2008 – 2010
  Sponsor: St. Jude Medical Center
  NCT00418314
• ENGAGE: Phase III, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus Warfarin in subjects with Atrial Fibrillation – Effective Anticoagulation with Xa next Generation in Atrial Fibrillation (ENGAGE – AF TIMI – 48).
  Sub-Investigator | 2009 – 2015
  Sponsor: Daiichi Sankyo Pharma Development
  NCT00781391

California, 1989